To disseminate the findings generated in VALUE-Dx by using various forms of communication and educational activities and publications at all levels of stakeholder platforms to promote their uptake and implementation in daily clinical practice and policy
To develop innovative, effective ways to disseminate information for creating awareness of optimal diagnosis and prognosis of CA-ARTI to prevent unnecessary prescription and use of antibiotics, to improve coverage with antibiotics, and thus limit antibiotic resistance and associated health and socioeconomic impacts
To develop and to tailor materials to support the adoption of CA-ARTI-Dx in European community care settings
https://www.value-dx.eu/wp-content/uploads/2019/07/shutterstock_1030079398.jpg40006000Daniele Pazzolahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2021-04-21 09:36:392021-04-21 09:36:39VALUE-Dx investigates HTA, Reimbursement and Pricing of Diagnostic Tests for CA-ARTI
https://www.value-dx.eu/wp-content/uploads/2021/04/Stethoscope-and-laptop-scaled.jpg17072560Daniele Pazzolahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2021-04-01 08:19:092021-04-01 08:20:35Funding models and health economics of diagnostics
https://www.value-dx.eu/wp-content/uploads/2020/06/Antibiotic-pills-Hand-Converted.jpg24822481Daniele Pazzolahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2021-03-31 07:17:282021-03-31 07:18:42Enhancing the quality of antibiotic prescribing for CA-ARTI in Emergency Rooms through ADEQUATE trial
https://www.value-dx.eu/wp-content/uploads/2019/07/shutterstock_457866949.jpg38405760Daniele Pazzolahttps://www.value-dx.eu/wp-content/uploads/2019/07/Logo-300x124.pngDaniele Pazzola2021-03-30 13:23:232021-04-01 07:34:54PRUDENCE trial will start in the summer of 2021
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.